GLP-1s linked to lean-mass loss risk

Diabetes in Control published an article on May 13 warning that patients taking GLP-1 drugs such as semaglutide and tirzepatide may lose lean mass as appetite falls and food intake drops. The piece said clinicians should look beyond the number on the scale and pay closer attention to body composition, protein intake and physical performance during treatment. It cited analyses in which lean mass made up roughly 25% to 40% of total weight lost on therapy. Those concerns have also appeared in recent medical literature and in a 2025 joint advisory from four obesity and nutrition groups. ### How much lean mass are clinicians worried about losing? Diabetes in Control said clinical trials of GLP-1 receptor agonists consistently show large reductions in body weight, but several studies also report measurable declines in lean body mass. The article said some analyses found lean mass accounted for about one-quarter to two-fifths of total weight lost during treatment. (diabetesincontrol.com) A 2025 editorial in BMJ Nutrition, Prevention & Health said lean-mass loss is not unique to GLP-1 drugs and also occurs with caloric restriction. The authors wrote that the debate is whether the loss seen with these medicines reflects harmful muscle wasting, expected adaptation during weight loss, or a mix that varies by patient. ### Why would GLP-1 drugs affect muscle in the first place? (diabetesincontrol.com) Diabetes in Control said reduced appetite is one reason clinicians are paying attention. The article said patients on GLP-1 therapy often eat less overall and may struggle to consume enough protein and other nutrients to support muscle protein synthesis. The 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society listed calorie reduction, nutritional deficiencies, and muscle and bone loss among the practical challenges that can accompany GLP-1 treatment. (pmc.ncbi.nlm.nih.gov) The paper said clinicians should assess usual dietary habits, muscle strength, function and body composition when patients start therapy. (diabetesincontrol.com) ### Which patients are most exposed to the risk? Diabetes in Control said older adults and people already vulnerable to sarcopenia may face greater concern when weight falls quickly. The article also said even modest declines in lean mass can affect strength and endurance if patients are physically inactive or nutritionally depleted. The BMJ Nutrition, Prevention & Health editorial said body-composition changes should be interpreted carefully because “lean mass” on scans can include more than skeletal muscle. (pmc.ncbi.nlm.nih.gov) The authors said some of what is measured as lean-mass loss may reflect reductions in water, liver tissue or other non-fat compartments rather than a direct loss of contractile muscle alone. (diabetesincontrol.com) ### What are clinicians being told to do differently? Diabetes in Control said dietary counseling should be part of routine GLP-1 care, with attention to preserving protein intake as appetite falls. The article advised clinicians to monitor nutrition and encourage resistance training to reduce the risk that weight loss comes at the expense of muscle. The four-group advisory went further, calling for a comprehensive exam that includes muscle strength, function and body-composition assessment, along with a lifestyle review covering strength training, aerobic activity, sleep and stress. (pmc.ncbi.nlm.nih.gov) The paper said GLP-1 treatment works best when paired with multicomponent nutrition and behavioral support rather than medication alone. (diabetesincontrol.com) ### Is this settled science or an active debate? A May 2026 article from the American Council on Science and Health said the “muscle scare” around GLP-1 drugs may overstate the evidence because body-composition tools do not always distinguish muscle from other lean tissue. That view aligns with the BMJ Nutrition, Prevention & Health editorial, which said lean-mass loss during weight reduction is common and should not automatically be read as drug-induced muscle damage. (pmc.ncbi.nlm.nih.gov) The next step is likely to come from clinical guidance and follow-up studies rather than a single ruling. The 2025 joint advisory is already being used as a framework for practice, and Diabetes in Control directed readers this week to protein monitoring and resistance training as immediate steps for patients starting or continuing GLP-1 therapy. (pmc.ncbi.nlm.nih.gov) (acsh.org)